Roche Extends Tender Offer for FMI

PRESS RELEASE

Basel, 2 March 2015

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has extended the expiration of its tender offer to purchase up to 15,604,288 of the outstanding common shares of Foundation Medicine, Inc. (NASDAQ: FMI), at a price of $50.00 per share in cash, to 12:00 midnight, New York City time, at the end of the day on Monday, April 6, 2015. All other terms and conditions of the tender offer remain unchanged.

As of March 1, 2015, approximately 7,739,202 common shares of FMI (none of which were tendered by notice of guaranteed delivery) had been tendered and not withdrawn pursuant to the tender offer.

Subject to satisfaction or waiver of the remaining conditions to the tender offer (including receipt at the special meeting, currently scheduled for April 2, 2015, of the required approval of FMI’s stockholders), Roche does not currently anticipate a further extension to the tender offer.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2014 the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.